Episode 14: Shlomi Raz, Palomar Labs

On this podcast episode, I speak with Shlomi Raz, Managing Partner at Palomar Labs. As a Venture Builder, Palomar Labs builds companies around medicines that already have a record of use in people, focused on the aging brain.

Shlomi started his career in Finance on Wall Street, and then transitioned into Biotech, as Founder and CEO of Eleusis. Beckley Psytech acquired Eleusis, and Shlomi served as President and CEO during BPL-003's clinical development.

Within Psychiatry, Palomar has taken a unique approach to drug development, starting with human experience (rather than animal models) along with the large set of existing data sets to identify the right compounds. And this approach may lend itself to other indications within Neuropsychiatry.

In our conversation, we touch upon the evolution of Psychedelics and the promise of ‘Generation 3,’ how JnJ’s SPRAVATO eventually became a blockbuster drug, what the venture building process looks like at Palomar Labs, and why the firm is focusing on unmet needs within aging.

Check out the full episode!